Voiding dysfunction after colpectomy and urethral lengthening in transgender men.
Colpectomy
gender-affirming surgery
transgender
urethral lengthening
urinary retention
voiding dysfunction
Journal
International journal of transgender health
ISSN: 2689-5277
Titre abrégé: Int J Transgend Health
Pays: United States
ID NLM: 101765532
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
30
1
2023
pubmed:
17
5
2021
medline:
17
5
2021
Statut:
epublish
Résumé
Colpectomy is a frequent part of gender-affirming surgery in transgender men. Urologic complications with these procedures can complicate and delay further management. Aim: We reviewed the rate of postoperative voiding dysfunction after colpectomy with urethral lengthening in transgender men. We reviewed postoperative voiding in 47 transgender men (age, 19-50 years) who underwent colpectomy with urethral lengthening. Thirty-eight patients (81%) had undergone hysterectomy (36 total, 2 subtotal/supracervical) previously and 11 (23%) underwent concomitant hysterectomy or removal of the residual cervix (4 abdominal, 6 laparoscopic, 1 transvaginal). Colpectomy was done transvaginally by opening and developing laterally the vesicovaginal and rectovaginal spaces and then transecting the lateral vaginal attachments with bipolar vessel sealing. Urethral lengthening with an anterior vaginal flap was performed in the same procedure as colpectomy. A transurethral catheter was left in situ for 14 days postoperatively. Voiding dysfunction was defined as failure of spontaneous micturition after removal of the catheter at 14 days. 40/47 (85%) patients were able to void after catheter removal, 7 (15%) were not. Voiding dysfunction occurred in 3/11 (27%) patients undergoing concomitant hysterectomy or removal of a residual cervix and in 4/36 patients (11%) status post total hysterectomy. Voiding dysfunction persisted for a median of 3 months (2 days - 46 months). In this series voiding dysfunction developed in 15% of transgender men undergoing colpectomy with urethral lengthening and appeared to be more common in patients undergoing concomitant hysterectomy or removal of a residual cervix than in those status post hysterectomy. Patients should be counseled accordingly.
Sections du résumé
Background
UNASSIGNED
Colpectomy is a frequent part of gender-affirming surgery in transgender men. Urologic complications with these procedures can complicate and delay further management. Aim: We reviewed the rate of postoperative voiding dysfunction after colpectomy with urethral lengthening in transgender men.
Methods
UNASSIGNED
We reviewed postoperative voiding in 47 transgender men (age, 19-50 years) who underwent colpectomy with urethral lengthening. Thirty-eight patients (81%) had undergone hysterectomy (36 total, 2 subtotal/supracervical) previously and 11 (23%) underwent concomitant hysterectomy or removal of the residual cervix (4 abdominal, 6 laparoscopic, 1 transvaginal). Colpectomy was done transvaginally by opening and developing laterally the vesicovaginal and rectovaginal spaces and then transecting the lateral vaginal attachments with bipolar vessel sealing. Urethral lengthening with an anterior vaginal flap was performed in the same procedure as colpectomy. A transurethral catheter was left in situ for 14 days postoperatively. Voiding dysfunction was defined as failure of spontaneous micturition after removal of the catheter at 14 days.
Results
UNASSIGNED
40/47 (85%) patients were able to void after catheter removal, 7 (15%) were not. Voiding dysfunction occurred in 3/11 (27%) patients undergoing concomitant hysterectomy or removal of a residual cervix and in 4/36 patients (11%) status post total hysterectomy. Voiding dysfunction persisted for a median of 3 months (2 days - 46 months).
Conclusions
UNASSIGNED
In this series voiding dysfunction developed in 15% of transgender men undergoing colpectomy with urethral lengthening and appeared to be more common in patients undergoing concomitant hysterectomy or removal of a residual cervix than in those status post hysterectomy. Patients should be counseled accordingly.
Identifiants
pubmed: 36713147
doi: 10.1080/26895269.2021.1924916
pii: 1924916
pmc: PMC9879163
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108-112Informations de copyright
© 2021 Taylor & Francis Group, LLC.
Références
Gynecol Oncol. 2021 Mar;160(3):729-734
pubmed: 33419610
Eur J Gynaecol Oncol. 1991;12(1):27-30
pubmed: 2050156
Int Urogynecol J. 2018 Oct;29(10):1463-1468
pubmed: 29188324
N Engl J Med. 2019 Dec 19;381(25):2451-2460
pubmed: 31851801
Int Urogynecol J. 2010 Jan;21(1):95-101
pubmed: 19760355
J Minim Invasive Gynecol. 2013 Jan-Feb;20(1):49-55
pubmed: 23131702
Plast Reconstr Surg. 2020 Jan;145(1):153e-161e
pubmed: 31881624
J Sex Med. 2019 Jun;16(6):924-933
pubmed: 31036523
Eur J Obstet Gynecol Reprod Biol. 1999 Nov;87(1):35-7
pubmed: 10579614
J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):404-9
pubmed: 26767825
Surg Endosc. 2017 Aug;31(8):3363-3369
pubmed: 27844235
Plast Reconstr Surg. 2017 Oct;140(4):551e-558e
pubmed: 28953722
J Minim Invasive Gynecol. 2020 Nov - Dec;27(7):1490-1502.e3
pubmed: 32730989
J Urol. 2018 Dec;200(6):1315-1322
pubmed: 30012365